Coronavirus disease 2019 (COVID-19) is a contagious disease caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2). The first case was identified in Wuhan
, China, in December 2019
The disease has since spread worldwide, leading to an ongoing pandemic
Symptoms of COVID-19
are variable, but often include fever, cough, fatigue, breathing difficulties
, and loss of smell
. Symptoms may begin one to fourteen days after exposure
to the virus. At least a third of people who are infected do not develop noticeable symptoms
. Of those people who develop noticeable symptoms enough to be classed as patients, most (81%) develop mild to moderate symptoms (up to mild pneumonia
), while 14% develop severe symptoms (dyspnea
, or more than 50% lung involvement on imaging), and 5% suffer critical symptoms (respiratory failure
, or multiorgan dysfunction
are more likely to have severe symptoms. Some people continue to experience a range of effects—known as long COVID
—for months after recovery, and damage to organs has been observed.
Multi-year studies are underway to further investigate the long-term effects of the disease.
The virus that causes COVID-19 spreads mainly when an infected person is in close contact with another person.
s containing the virus can spread from an infected person's nose and mouth as they breathe, cough, sneeze, sing, or speak. Other people are infected if the virus gets into their mouth, nose or eyes. The virus may also spread via contaminated surfaces
, although this is not thought to be the main route of transmission.
The exact route of transmission is rarely proven conclusively, but infection mainly happens when people are near each other for long enough. People who are infected can transmit the virus to another person up to two days before they themselves show symptoms, as can people who do not experience symptoms. People remain infectious for up to ten days after the onset of symptoms in moderate cases and up to 20 days in severe cases.
Several testing methods
have been developed to diagnose
the disease. The standard diagnostic method is by detection of the virus' nucleic acid
by real-time reverse transcription polymerase chain reaction
(rRT-PCR), transcription-mediated amplification
(TMA), or by reverse transcription loop-mediated isothermal amplification
(RT-LAMP) from a nasopharyngeal swab
include physical or social distancing
, ventilation of indoor spaces, covering coughs and sneezes, hand washing
, and keeping unwashed hands away from the face. The use of face masks or coverings
has been recommended in public settings to minimise the risk of transmissions. Several vaccines
have been developed and several countries have initiated mass vaccination campaigns.
Although work is underway to develop drugs
that inhibit the virus, the primary treatment
is symptomatic. Management involves the treatment of symptoms
, supportive care
, and experimental measures
During the initial outbreak in Wuhan
, China, the virus and disease were commonly referred to as "coronavirus" and "Wuhan coronavirus", with the disease sometimes called "Wuhan pneumonia". In the past, many diseases have been named after geographical locations, such as the Spanish flu
, Middle East Respiratory Syndrome
, and Zika virus
In January 2020, the WHO recommended 2019-nCov and 2019-nCoV acute respiratory disease as interim names for the virus and disease per 2015 guidance and international guidelines against using geographical locations (e.g. Wuhan, China), animal species, or groups of people in disease and virus names in part to prevent social stigma
The official names COVID-19 and SARS-CoV-2 were issued by the WHO on 11 February 2020.
Tedros Adhanom explained: CO for ''corona'', VI for ''virus'', Dfor ''disease'' and 19 for when the outbreak was first identified (31 December 20''19''). The WHO additionally uses "the COVID-19 virus" and "the virus responsible for COVID-19" in public communications.
Signs and symptoms
COVID-19 is caused by infection with the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) virus strain.
Coronavirus disease 2019 (COVID-19)COVID-19
spreads from person to person mainly through the respiratory route after an infected person coughs, sneezes, sings, talks or breathes.
A new infection occurs when virus-containing particles exhaled by an infected person, either respiratory droplet
s or aerosol
s, get into the mouth, nose, or eyes of other people who are in close contact with the infected person.
During human-to-human transmission, an average 1000 infectious SARS-CoV-2 virions are thought to initiate a new infection.
The closer people interact, and the longer they interact, the more likely they are to transmit COVID-19. Closer distances can involve larger droplets (which fall to the ground) and aerosols, whereas longer distances only involve aerosols.
Larger droplets can also turn into aerosols (known as droplet nuclei
) through evaporation.
The relative importance of the larger droplets and the aerosols is not clear as of November 2020; however, the virus is not known to spread between rooms over long distances such as through air ducts.
is able to particularly occur indoors, in high risk locations
such as restaurants, choirs, gyms, nightclubs, offices, and religious venues, often when they are crowded or less ventilated.
It also occurs in healthcare settings, often when aerosol-generating medical procedures
are performed on COVID-19 patients.
Although it is considered possible there is no direct evidence of the virus being transmitted by skin to skin contact.
A person could get COVID-19 indirectly
by touching a contaminated surface or object
before touching their own mouth, nose, or eyes, though this is not thought to be the main way the virus spreads.
The virus is not known to spread through feces
, breast milk
, drinking water
, or via animal disease vectors
(although some animals can contract the virus from humans). It very rarely transmits from mother to baby
and the wearing of cloth face masks, surgical masks, respirators, or other face coverings
are controls for droplet transmission. Transmission may be decreased indoors with well maintained heating and ventilation systems to maintain good air circulation and increase the use of outdoor air.
The number of people generally infected by one infected person varies.
COVID-19 is more infectious than influenza
, but less so than measles
. It often spreads in clusters
, where infections can be traced back to an index case or geographical location.
There is a major role of "super-spreading events
", where many people are infected by one person.
A person who is infected can transmit the virus to others up to two days before they themselves show symptoms, and even if symptoms never appear.
People remain infectious in moderate cases for 7–12 days, and two weeks or more in severe cases.
In October 2020, medical scientists reported evidence of reinfection in one person.
Severe acute respiratory syndrome coronavirus2 (SARS-CoV-2) is a novel
severe acute respiratory syndrome coronavirus. It was first isolated from three people with pneumonia connected to the cluster
of acute respiratory illness cases in Wuhan.
All structural features of the novel SARS-CoV-2 virus particle occur in related coronavirus
es in nature.
Outside the human body, the virus is destroyed by household soap, which bursts its protective bubble
SARS-CoV-2 is closely related to the original SARS-CoV
It is thought to have an animal (zoonotic
) origin. Genetic analysis has revealed that the coronavirus genetically clusters with the genus ''Betacoronavirus
'', in subgenus ''Sarbecovirus''
(lineage B) together with two bat-derived strains. It is 96% identical at the whole genome
level to other bat coronavirus samples (BatCov RaTG13
The structural proteins of SARS-CoV-2 include membrane glycoprotein (M), envelope protein (E), nucleocapsid protein (N), and the spike protein (S). The M protein of SARS-CoV-2 is about 98% similar to the M protein of bat SARS-CoV, maintains around 98% homology with pangolin SARS-CoV, and has 90% homology with the M protein of SARS-CoV; whereas, the similarity is only around 38% with the M protein of MERS-CoV. The structure of the M protein resembles the sugar transporter SemiSWEET.
The many thousands of SARS-CoV-2 variants are grouped into clade
s. Several different clade nomenclatures
have been proposed. Nextstrain
divides the variants into five clades (19A, 19B, 20A, 20B, and 20C), while GISAID
divides them into seven (L, O, V, S, G, GH, and GR).
Several notable variants of SARS-CoV-2 emerged in late 2020. Cluster 5
emerged among mink
s and mink farmers in Denmark. After strict quarantines and a mink euthanasia campaign, it is believed to have been eradicated. The Variant of Concern 202012/01
(VOC 202012/01) is believed to have emerged in the United Kingdom in September. The 501Y.V2 Variant
, which has the same N501Y mutation, arose independently in South Africa.
Three known variants of SARS-CoV-2 are spreading among global populations , including the UK Variant (referred to as B.1.1.7
) first found in London and Kent, a variant discovered in South Africa (referred to as 1.351
), and a variant discovered in Brazil (referred to as P.1
Using Whole Genome Sequencing, epidemiology and modelling suggest the new UK variant ‘VUI – 202012/01’ (the first Variant Under Investigation in December 2020) transmits more easily than other strains.
COVID-19 can affect the upper respiratory tract (sinuses, nose, and throat) and the lower respiratory tract (windpipe and lungs).
The lungs are the organs most affected by COVID-19 because the virus accesses host cells via the enzyme angiotensin-converting enzyme 2
(ACE2), which is most abundant in type II alveolar cells
of the lungs. The virus uses a special surface glycoprotein called a "spike" (peplomer
) to connect to ACE2 and enter the host cell.
The density of ACE2 in each tissue correlates with the severity of the disease in that tissue and decreasing ACE2 activity might be protective, though another view is that increasing ACE2 using angiotensin II receptor blocker
medications could be protective. As the alveolar disease progresses, respiratory failure might develop and death may follow.
Whether SARS-CoV-2 is able to invade the nervous system remains unknown however it is clear that many people with COVID-19 exhibit neurological or mental health issues
. The virus is not detected in the CNS
of the majority of COVID-19 people with neurological issues
. However, SARS-CoV-2 has been detected at low levels in the brains of those who have died from COVID-19, but these results need to be confirmed.
Loss of smell results from infection of the support cells of the olfactory epithelium
, with subsequent damage to the olfactory neurons
SARS-CoV-2 could cause respiratory failure through affecting the brain stem as other coronaviruses have been found to invade the CNS. While virus has been detected in cerebrospinal fluid of autopsies, the exact mechanism by which it invades the CNS remains unclear and may first involve invasion of peripheral nerves given the low levels of ACE2 in the brain. The virus may also enter the bloodstream from the lungs and cross the blood-brain barrier to gain access to the CNS, possibly within an infected white blood cell.
The virus also affects gastrointestinal organs as ACE2 is abundantly expressed in the gland
ular cells of gastric
and rectal epithelium
as well as endothelial
cells and enterocyte
s of the small intestine
The virus can cause acute myocardial injury
and chronic damage to the cardiovascular system
An acute cardiac injury was found in 12% of infected people admitted to the hospital in Wuhan, China,
and is more frequent in severe disease. Rates of cardiovascular symptoms are high, owing to the systemic inflammatory response and immune system disorders during disease progression, but acute myocardial injuries may also be related to ACE2 receptors in the heart.
ACE2 receptors are highly expressed in the heart and are involved in heart function.
A high incidence of thrombosis
and venous thromboembolism
have been found people transferred to Intensive care unit
(ICU) with COVID-19 infections, and may be related to poor prognosis. Blood vessel dysfunction and clot formation (as suggested by high D-dimer
levels caused by blood clots) are thought to play a significant role in mortality, incidences of clots leading to pulmonary embolism
s, and ischaemic events
within the brain have been noted as complications leading to death in people infected with SARS-CoV-2. Infection appears to set off a chain of vasoconstrictive responses
within the body, constriction of blood vessels within the pulmonary circulation
has also been posited as a mechanism in which oxygenation decreases alongside the presentation of viral pneumonia.
Furthermore, microvascular blood vessel damage
has been reported in a small number of tissue samples of the brains – without detected SARS-CoV-2 – and the olfactory bulbs from those who have died from COVID-19.
Another common cause of death is complications related to the kidney
Early reports show that up to 30% of hospitalized patients both in China and in New York have experienced some injury to their kidneys, including some persons with no previous kidney problems.
Autopsies of people who died of COVID-19 have found diffuse alveolar damage
, and lymphocyte-containing inflammatory infiltrates within the lung.
Although SARS-CoV-2 has a tropism for ACE2-expressing epithelial cells of the respiratory tract, people with severe COVID-19 have symptoms of systemic hyperinflammation. Clinical laboratory findings of elevated IL-2
, granulocyte-macrophage colony-stimulating factor
(GM-CSF), interferon-γ inducible protein 10
(IP-10), monocyte chemoattractant protein1
(MCP-1), macrophage inflammatory protein 1-α
(MIP-1α), and tumour necrosis factor-α
(TNF-α) indicative of cytokine release syndrome
(CRS) suggest an underlying immunopathology.
Additionally, people with COVID-19 and acute respiratory distress syndrome
(ARDS) have classical serum biomarker
s of CRS, including elevated C-reactive protein
(CRP), lactate dehydrogenase
, and ferritin
Systemic inflammation results in vasodilation
, allowing inflammatory lymphocytic and monocytic infiltration of the lung and the heart. In particular, pathogenic GM-CSF-secreting T-cells
were shown to correlate with the recruitment of inflammatory IL-6-secreting monocyte
s and severe lung pathology in people with COVID-19. Lymphocytic infiltrates have also been reported at autopsy.
Viral and host factors
Multiple viral and host factors affect the pathogenesis of the virus. The S-protein, otherwise known as the spike protein, is the viral component that attaches to the host receptor via the ACE2
receptors. It includes two subunits: S1 and S2. S1 determines the virus host range and cellular tropism via the receptor binding domain. S2 mediates the membrane fusion of the virus to its potential cell host via the H1 and HR2, which are heptad repeat
regions. Studies have shown that S1 domain induced IgG
antibody levels at a much higher capacity. It is the focus spike proteins expression that are involved in many effective COVID-19 vaccines.
The M protein is the viral protein responsible for the transmembrane transport of nutrients. It is the cause of the bud release and the formation of the viral envelope.
The N and E protein are accessory proteins that interfere with the host's immune response.
Human angiotensin converting enzyme 2
(hACE2) is the host factor that SARS-COV2 virus targets causing COVID-19. Theoretically the usage of angiotensin receptor blockers
(ARB) and ACE inhibitor
s upregulating ACE2 expression might increase morbidity with COVID-19, though animal data suggest some potential protective effect of ARB. However no clinical studies have proven susceptibility or outcomes. Until further data is available, guidelines and recommendations for hypertensive patients remain.
The virus' effect on ACE2 cell surfaces leads to leukocytic infiltration, increased blood vessel permeability, alveolar wall permeability, as well as decreased secretion of lung surfactants. These effects cause the majority of the respiratory symptoms. However, the aggravation of local inflammation causes a cytokine storm eventually leading to a systemic inflammatory response syndrome
Host cytokine response
The severity of the inflammation can be attributed to the severity of what is known as the cytokine storm
Levels of interleukin 1B
, interferon-inducible protein 10, and monocyte chemoattractant protein 1 were all associated with COVID-19 disease severity. Treatment has been proposed to combat the cytokine storm as it remains to be one of the leading causes of morbidity
and mortality in COVID-19 disease.
A cytokine storm is due to an acute hyperinflammatory response that is responsible for clinical illness in an array of diseases but in COVID-19, it is related to worse prognosis and increased fatality. The storm causes the acute respiratory distress syndrome, blood clotting events such as strokes, myocardial infarction, encephalitis, acute kidney injury
, and vasculitis. The production of IL-1
, and interferon-gamma
, all crucial components of normal immune responses, inadvertently become the causes of a cytokine storm. The cells of the central nervous system
, the microglia
s, and astrocyte
s, are also involved in the release of pro-inflammatory cytokines affecting the nervous system, and effects of cytokine storms toward the CNS
are not uncommon.
COVID-19 can provisionally be diagnosed on the basis of symptoms and confirmed using reverse transcription polymerase chain reaction
(RT-PCR) or other nucleic acid
testing of infected secretions.
Along with laboratory testing, chest CT scans may be helpful to diagnose COVID-19 in individuals with a high clinical suspicion of infection.
Detection of a past infection is possible with serological tests
, which detect antibodies
produced by the body in response to the infection.
The standard methods of testing for presence of SARS-CoV-2 are nucleic acid test
which detects the presence of viral RNA fragments.
As these tests detect RNA but not infectious virus, its "ability to determine duration of infectivity of patients is limited."
The test is typically done on respiratory samples obtained by a nasopharyngeal swab
; however, a nasal swab or sputum sample may also be used.
Results are generally available within hours.
The WHO has published several testing protocols for the disease.
A number of laboratories and companies have developed serological tests, which detect antibodies produced by the body in response to infection. Several have been evaluated by Public Health England
and approved for use in the UK.
The University of Oxford
's CEBM has pointed to mounting evidence
that "a good proportion of 'new' mild cases and people re-testing positives after quarantine or discharge from hospital are not infectious, but are simply clearing harmless virus particles which their immune system has efficiently dealt with" and have called for "an international effort to standardize and periodically calibrate testing"
On 7 September, the UK government issued "guidance for procedures to be implemented in laboratories to provide assurance of positive SARS-CoV-2 RNA results during periods of low prevalence, when there is a reduction in the predictive value of positive test results."
Chest CT scans may be helpful to diagnose COVID-19 in individuals with a high clinical suspicion of infection but are not recommended for routine screening.
Bilateral multilobar ground-glass opacities
with a peripheral, asymmetric, and posterior distribution are common in early infection.
Subpleural dominance, crazy paving
(lobular septal thickening with variable alveolar filling), and consolidation
may appear as the disease progresses.
Characteristic imaging features on chest radiographs
and computed tomography
(CT) of people who are symptomatic include asymmetric peripheral ground-glass opacities without pleural effusion
Many groups have created COVID-19 datasets
that include imagery such as the Italian Radiological Society
which has compiled an international online database of imaging findings for confirmed cases.
Due to overlap with other infections such as adenovirus
, imaging without confirmation by rRT-PCR is of limited specificity
in identifying COVID-19.
A large study in China compared chest CT results to PCR and demonstrated that though imaging is less specific for the infection, it is faster and more sensitive
In late 2019, the WHO assigned emergency ICD-10
disease codes U07.1 for deaths from lab-confirmed SARS-CoV-2 infection and U07.2 for deaths from clinically or epidemiologically diagnosed COVID-19 without lab-confirmed SARS-CoV-2 infection.
The main pathological findings at autopsy are:
, lung consolidation
and pulmonary oedema
* Lung findings:
** minor serous exudation
, minor fibrin
** pulmonary oedema, pneumocyte hyperplasia
, large atypical pneumocyte
s, interstitial inflammation
with lymphocytic infiltration
and multinucleated giant cell
** diffuse alveolar damage
(DAD) with diffuse alveolar exudates
. DAD is the cause of acute respiratory distress syndrome
(ARDS) and severe hypoxemia
s in alveolar cavities
and pulmonary interstitial fibrosis
* Blood: disseminated intravascular coagulation
(DIC); leukoerythroblastic reaction
* Liver: microvesicular steatosis
*Nose: shedding of olfactory epithelium
Preventive measures to reduce the chances of infection include staying at home, wearing a mask in public, avoiding crowded places, keeping distance from others, ventilating indoor spaces, washing hands with soap and water often and for at least 20 seconds, practising good respiratory hygiene, and avoiding touching the eyes, nose, or mouth with unwashed hands.
Those diagnosed with COVID-19 or who believe they may be infected are advised by the CDC to stay home except to get medical care, call ahead before visiting a healthcare provider, wear a face mask
before entering the healthcare provider's office and when in any room or vehicle with another person, cover coughs and sneezes with a tissue, regularly wash hands with soap and water and avoid sharing personal household items.
The first COVID-19 vaccine
was granted regulatory approval on 2 December by the UK medicines regulator MHRA
It was evaluated for emergency use authorization
(EUA) status by the US FDA
, and in several other countries.
Initially, the US National Institutes of Health
guidelines do not recommend any medication for prevention of COVID-19, before or after exposure to the SARS-CoV-2 virus, outside the setting of a clinical trial.
Without a vaccine, other prophylactic measures, or effective treatments, a key part of managing COVID-19 is trying to decrease and delay the epidemic peak, known as "flattening the curve
This is done by slowing the infection rate to decrease the risk of health services being overwhelmed, allowing for better treatment of current cases, and delaying additional cases until effective treatments or a vaccine become available.
Social distancing (also known as physical distancing) includes infection control
actions intended to slow the spread of the disease by minimising close contact between individuals. Methods include quarantines; travel restrictions; and the closing of schools, workplaces, stadiums, theatres, or shopping centres. Individuals may apply social distancing methods by staying at home, limiting travel, avoiding crowded areas, using no-contact greetings, and physically distancing themselves from others.
Many governments are now mandating or recommending social distancing in regions affected by the outbreak.
Outbreaks have occurred in prisons due to crowding and an inability to enforce adequate social distancing.
In the United States, the prisoner population is aging and many of them are at high risk for poor outcomes from COVID-19 due to high rates of coexisting heart and lung disease, and poor access to high-quality healthcare.
at home has been recommended for those diagnosed with COVID-19 and those who suspect they have been infected. Health agencies have issued detailed instructions for proper self-isolation.
Many governments have mandated or recommended self-quarantine for entire populations. The strongest self-quarantine instructions have been issued to those in high-risk groups.
Those who may have been exposed to someone with COVID-19 and those who have recently travelled to a country or region with the widespread transmission have been advised to self-quarantine for 14 days from the time of last possible exposure.
Face masks and respiratory hygiene
The WHO and the US CDC recommend individuals wear non-medical face coverings in public settings where there is an increased risk of transmission and where social distancing measures are difficult to maintain.
This recommendation is meant to reduce the spread of the disease by asymptomatic and pre-symptomatic individuals and is complementary to established preventive measures such as social distancing.
Face coverings limit the volume and travel distance of expiratory droplets dispersed when talking, breathing, and coughing.
A face covering without vents or holes will also filter out particles containing the virus from inhaled and exhaled air, reducing the chances of infection.
But, if the mask include an exhalation valve
, a wearer that is infected (maybe without having noticed that, and asymptomatic) would transmit the virus outwards through it, despite any certification they can have. So the masks with exhalation valve
are not for the infected wearers, and are not reliable to stop the pandemic in a large scale. Many countries and local jurisdictions encourage or mandate the use of face masks or cloth face coverings by members of the public to limit the spread of the virus.
Masks are also strongly recommended for those who may have been infected and those taking care of someone who may have the disease.
When not wearing a mask, the CDC recommends covering the mouth and nose with a tissue when coughing or sneezing and recommends using the inside of the elbow if no tissue is available. Proper hand hygiene after any cough or sneeze is encouraged. Healthcare professionals interacting directly with people who have COVID-19 are advised to use respirator
s at least as protective as NIOSH
or equivalent, in addition to other personal protective equipment
Hand-washing and hygiene
Thorough hand hygiene after any cough or sneeze is required.
The WHO also recommends that individuals wash hands often with soap and water for at least 20 seconds, especially after going to the toilet or when hands are visibly dirty, before eating and after blowing one's nose.
When soap and water are not available, the CDC recommends using an alcohol-based hand sanitiser
with at least 60% alcohol. For areas where commercial hand sanitisers are not readily available, the WHO provides two formulations for local production. In these formulations, the antimicrobial activity arises from ethanol
. Hydrogen peroxide
is used to help eliminate bacterial spores
in the alcohol; it is "not an active substance for hand antisepsis
is added as a humectant
After being expelled from the body, coronaviruses can survive on surfaces for hours to days. If a person touches the dirty surface, they may deposit the virus at the eyes, nose, or mouth where it can enter the body cause infection.
Current evidence indicates that contact with infected surfaces is not the main driver of COVID-19, leading to recommendations for optimised disinfection procedures to avoid issues such as the increase of antimicrobial resistance
through the use of inappropriate cleaning products and processes.
ing and other surface sanitation has been criticized as hygiene theater
, giving a false sense of security against something primarily spread through the air.
The amount of time that the virus can survive depends significantly on the type of surface, the temperature, and the humidity.
Coronaviruses die very quickly when exposed to the UV light
Like other enveloped viruses, SARS-CoV-2 survives longest when the temperature is at room temperature
or lower, and when the relative humidity
is low (<50%).
On many surfaces, including as glass, some types of plastic, stainless steel, and skin, the virus can remain infective for several days indoors at room temperature, or even about a week under ideal conditions.
On some surfaces, including cotton fabric and copper, the virus usually dies after a few hours.
As a rule of thumb, the virus dies faster on porous surfaces than on non-porous surfaces.
However, this rule is not absolute, and of the many surfaces tested, two with the longest survival times are N95 respirator masks and surgical masks, both of which are considered porous surfaces.
Surfaces may be decontaminated with 62–71 percent ethanol
, 50–100 percent isopropanol, 0.1 percent sodium hypochlorite
, 0.5 percent hydrogen peroxide, and 0.2–7.5 percent povidone-iodine
. Other solutions, such as benzalkonium chloride
and chlorhexidine gluconate
, are less effective. Ultraviolet germicidal irradiation
may also be used.
The CDC recommends that if a COVID-19 case is suspected or confirmed at a facility such as an office or day care, all areas such as offices, bathrooms, common areas, shared electronic equipment like tablets, touch screens, keyboards, remote controls, and ATM machines used by the ill persons should be disinfected.
A datasheet comprising the authorised substances to disinfection in the food industry (including suspension or surface tested, kind of surface, use dilution, disinfectant and inocuylum volumes) can be seen in the supplementary material of.
Ventilation and air filtration
The WHO recommends ventilation
and air filtration
in public spaces to help clear out infectious aerosols.
Healthy diet and lifestyle
The Harvard T.H. Chan School of Public Health
recommends a healthy diet, being physically active, managing psychological stress, and getting enough sleep.
While there is no evidence that vitamin D is an effective treatment for COVID-19, there is limited evidence that vitamin D deficiency
increases the risk of severe COVID-19 symptoms.
The severity of COVID-19 varies. The disease may take a mild course with few or no symptoms, resembling other common upper respiratory diseases such as the common cold
. In 3–4% of cases (7.4% for those over age 65) symptoms are severe enough to cause hospitalization.
Mild cases typically recover within two weeks, while those with severe or critical diseases may take three to six weeks to recover. Among those who have died, the time from symptom onset to death has ranged from two to eight weeks.
The Italian Istituto Superiore di Sanità
reported that the median time between the onset of symptoms and death was twelve days, with seven being hospitalised. However, people transferred to an ICU had a median time of ten days between hospitalisation and death.
Prolonged prothrombin time and elevated C-reactive protein levels on admission to the hospital are associated with severe course of COVID-19 and with a transfer to ICU.
Some early studies suggest 10% to 20% of people with COVID-19 will experience symptoms lasting longer than a month
A majority of those who were admitted to hospital with severe disease report long-term problems including fatigue and shortness of breath.
On 30 October 2020 WHO chief Tedros Adhanom
warned that "to a significant number of people, the COVID virus poses a range of serious long-term effects". He has described the vast spectrum of COVID-19 symptoms that fluctuate over time as "really concerning." They range from fatigue, a cough and shortness of breath, to inflammation and injury of major organs – including the lungs and heart, and also neurological and psychologic effects. Symptoms often overlap and can affect any system in the body. Infected people have reported cyclical bouts of fatigue, headaches, months of complete exhaustion, mood swings, and other symptoms. Tedros has concluded that therefore herd immunity
is "morally unconscionable and unfeasible".
In terms of hospital readmissions about 9% of 106,000 individuals had to return for hospital treatment within 2 months of discharge. The average to readmit was 8 days since first hospital visit. There are several risk factors that have been identified as being a cause of multiple admissions to a hospital facility. Among these are advanced age (above 65 years of age) and presence of a chronic condition such as diabetes, COPD, heart failure or chronic kidney disease.
According to scientific review
s smokers are more likely to require intensive care or die compared to non-smokers,
air pollution is similarly associated with risk factors,
and pre-existing heart and lung diseases and also obesity
contributes to an increased health risk of COVID-19.
It is also assumed that those that are immunocompromised are at higher risk of getting severely sick from SARS-CoV-2. One research that looked into the COVID-19 infections in hospitalized kidney transplant recipients found a mortality rate of 11%.
also plays an important role in the ability to fight off the disease. For instance, those that do not produce detectable type I interferon
s or produce auto-antibodies
against these may get much sicker from COVID-19. Genetic screening
is able to detect interferon effector genes.
may be at higher risk of severe COVID-19 infection based on data from other similar viruses, like SARS and MERS, but data for COVID-19 is lacking.
While very young children have experienced lower rates of infection, older children have a rate of infection that is similar to the population as a whole. Children are likely to have milder symptoms and are at lower risk of severe disease than adults. The CDC reports that in the US roughly a third of hospitalized children were admitted to the ICU, while a European multinational study of hospitalized children from June 2020 found that about 8% of children admitted to a hospital needed intensive care. Four of the 582 children (0.7%) in the European study died, but the actual mortality rate could be "substantially lower" since milder cases that did not seek medical help were not included in the study.
Complications may include pneumonia
, acute respiratory distress syndrome
(ARDS), multi-organ failure
, septic shock
, and death.
Cardiovascular complications may include heart failure, arrhythmia
s, heart inflammation
, and blood clots
Approximately 20–30% of people who present with COVID-19 have elevated liver enzymes
, reflecting liver injury.
Neurologic manifestations include seizure
, stroke, encephalitis
, and Guillain–Barré syndrome
(which includes loss of motor functions
Following the infection, children may develop paediatric multisystem inflammatory syndrome
, which has symptoms similar to Kawasaki disease
, which can be fatal. In very rare cases, acute encephalopathy
can occur, and it can be considered in those who have been diagnosed with COVID-19 and have an altered mental status.
Some early studies suggest that that 10 to 20% of people with COVID-19 will experience symptoms lasting longer than a month.
A majority of those who were admitted to hospital with severe disease report long-term problems, including fatigue and shortness of breath.
About 5-10% of patients admitted to hospital progress to severe or critical disease, including pneumonia and acute respiratory failure.
By a variety of mechanisms, the lungs are the organs most affected in COVID-19.
The majority of CT scans performed show lung abnormalities in people tested after 28 days of illness.
People with advanced age, severe disease, prolonged ICU stays, or who smoke are more likely to have long lasting effects, including pulmonary fibrosis.
Overall, approximately one third of those investigated after 4 weeks will have findings of pulmonary fibrosis
or reduced lung function as measured by DLCO
, even in people who are asymptomatic, but with the suggestion of continuing improvement with the passing of more time.
The immune response
by humans to CoV-2 virus occurs as a combination of the cell-mediated immunity
and antibody production, just as with most other infections. Since SARS-CoV-2 has been in the human population only since December 2019, it remains unknown if the immunity
is long-lasting in people who recover from the disease.
The presence of neutralizing antibodies in blood strongly correlates with protection from infection, but the level of neutralizing antibody declines with time. Those with asymptomatic or mild disease had undetectable levels of neutralizing antibody two months after infection. In another study, the level of neutralizing antibody fell 4-fold 1 to 4 months after the onset of symptoms. However, the lack of antibody in the blood does not mean antibody will not be rapidly produced upon reexposure to SARS-CoV-2. Memory B cells specific for the spike and nucleocapsid proteins of SARS-CoV-2 last for at least 6 months after appearance of symptoms.
Nevertheless, 15 cases of reinfection with SARS-CoV-2 have been reported using stringent CDC criteria requiring identification of a different variant from the second infection. There are likely to be many more people who have been reinfected with the virus. Herd immunity will not eliminate the virus if reinfection is common.
Some other coronaviruses circulating in people are capable of reinfection after roughly a year. Nonetheless, on 3 March 2021, scientists reported that a much more contagious COVID-19 variant
, Lineage P.1
, first detected in Japan, and subsequently found in Brazil, as well as in several places in the United States, may be associated with COVID-19 disease reinfection after recovery from an earlier COVID-19 infection.
Several measures are commonly used to quantify mortality. These numbers vary by region and over time and are influenced by the volume of testing, healthcare system quality, treatment options, time since the initial outbreak, and population characteristics such as age, sex, and overall health. The mortality rate
reflects the number of deaths within a specific demographic group divided by the population of that demographic group. Consequently, the mortality rate reflects the prevalence as well as the severity of the disease within a given population. Mortality rates are highly correlated to age, with relatively low rates for young people and relatively high rates among the elderly.
The case fatality rate
(CFR) reflects the number of deaths divided by the number of diagnosed cases within a given time interval. Based on Johns Hopkins University statistics, the global death-to-case ratio is (/) as of . The number varies by region. The CFR may not reflect the true severity of the disease, because some infected individuals remain asymptomatic or experience only mild symptoms, and hence such infections may not be included in official case reports. Moreover, the CFR may vary markedly over time and across locations due to the availability of live virus tests.
Total-cases-covid-19-who.png|Total confirmed cases over time
World map of total confirmed COVID-19 cases per million people.png|Total confirmed cases of COVID-19 per million people
Total-deaths-covid-19-who (1).png|Total deaths over time
World map of total confirmed COVID-19 deaths per million people by country.png|Total confirmed deaths due to COVID-19 per million people
Infection fatality rate
A key metric in gauging the severity of COVID-19 is the infection fatality rate
(IFR), also referred to as the ''infection fatality ratio'' or ''infection fatality risk''. This metric is calculated by dividing the total number of deaths from the disease by the total number of infected individuals; hence, in contrast to the CFR
, the IFR incorporates asymptomatic and undiagnosed infections as well as reported cases.
thumb|The same relationship plotted on a log scale
A December 2020 systematic review and meta-analysis estimated that population IFR during the first wave of the pandemic was about 0.5% to 1% in many locations (including France, Netherlands, New Zealand, and Portugal), 1% to 2% in other locations (Australia, England, Lithuania, and Spain), and exceeded 2% in Italy.
[ Text was copied from this source, which is available under ]
Creative Commons Attribution 4.0 International License
That study also found that most of these differences in IFR reflected corresponding differences in the age composition of the population and age-specific infection rates; in particular, the metaregression estimate of IFR is very low for children and younger adults (e.g., 0.002% at age 10 and 0.01% at age 25) but increases progressively to 0.4% at age 55, 1.4% at age 65, 4.6% at age 75, and 15% at age 85.
These results were also highlighted in a December 2020 report issued by the WHO.
Earlier estimates of IFR
At an early stage of the pandemic, the World Health Organization reported estimates of IFR between 0.3% and 1%. On 2July, The WHO's chief scientist reported that the average IFR estimate presented at a two-day WHO expert forum was about 0.6%.
In August, the WHO found that studies incorporating data from broad serology testing in Europe showed IFR estimates converging at approximately 0.5–1%. Firm lower limits of IFRs have been established in a number of locations such as New York City and Bergamo in Italy since the IFR cannot be less than the population fatality rate. As of 10July, in New York City, with a population of 8.4million, 23,377 individuals (18,758 confirmed and 4,619 probable) have died with COVID-19 (0.3% of the population). Antibody testing in New York City suggested an IFR of ~0.9%, and ~1.4%. In Bergamo province
, 0.6% of the population has died. In September 2020 the U.S. Center for Disease Control & Prevention reported preliminary estimates of age-specific IFRs for public health planning purposes.
Early reviews of epidemiologic data showed gendered impact of the pandemic and a higher mortality rate in men in China and Italy.
The Chinese Center for Disease Control and Prevention
reported the death rate was 2.8% for men and 1.7% for women. Later reviews in June 2020 indicated that there is no significant difference in susceptibility or in CFR between genders. One review acknowledges the different mortality rates in Chinese men, suggesting that it may be attributable to lifestyle choices such as smoking and drinking alcohol rather than genetic factors. Sex-based immunological differences, lesser prevalence of smoking in women and men developing co-morbid conditions such as hypertension at a younger age than women could have contributed to the higher mortality in men.
In Europe, 57% of the infected people were men and 72% of those died with COVID-19 were men. As of April 2020, the US government is not tracking sex-related data of COVID-19 infections.
Research has shown that viral illnesses like Ebola, HIV, influenza and SARS affect men and women differently.
In the US, a greater proportion of deaths due to COVID-19 have occurred among African Americans and other minority groups.
Structural factors that prevent them from practicing social distancing include their concentration in crowded substandard housing and in "essential" occupations such as retail grocery workers, public transit employees, health-care workers and custodial staff. Greater prevalence of lacking health insurance
and care and of underlying conditions such as diabetes
, hypertension and heart disease
also increase their risk of death. Similar issues affect Native American
According to a US health policy non-profit, 34% of American Indian and Alaska Native People (AIAN) non-elderly adults are at risk of serious illness compared to 21% of white non-elderly adults. The source attributes it to disproportionately high rates of many health conditions that may put them at higher risk as well as living conditions like lack of access to clean water. Leaders have called for efforts to research and address the disparities. In the U.K., a greater proportion of deaths due to COVID-19 have occurred in those of a Black
, and other ethnic minority background. More severe impacts upon victims including the relative incidence of the necessity of hospitalization requirements, and vulnerability to the disease has been associated via DNA analysis to be expressed in genetic variants at chromosomal region 3, features that are associated with European Neanderthal
heritage. That structure imposes greater risks that those affected will develop a more severe form of the disease.
[The ancient Neanderthal in severe COVID-19]
''Science News'', 30 September 2020. Retrieved 13 December 2020.
The findings are from Professor Svante Pääbo and researchers he leads at the Max Planck Institute for Evolutionary Anthropology
and the Karolinska Institutet
[ This admixture of modern human and Neanderthal genes is estimated to have occurred roughly between 50,000 and 60,000 years ago in Southern Europe.] [
Most of those who die of COVID-19 have pre-existing (underlying) conditions, including hypertension, diabetes mellitus, and cardiovascular disease.
According to March data from the United States, 89% of those hospitalised had preexisting conditions. The Italian Istituto Superiore di Sanità reported that out of 8.8% of deaths where medical charts were available, 96.1% of people had at least one comorbidity with the average person having 3.4 diseases. According to this report the most common comorbidities are hypertension (66% of deaths), type 2 diabetes (29.8% of deaths), Ischemic Heart Disease (27.6% of deaths), atrial fibrillation (23.1% of deaths) and chronic renal failure (20.2% of deaths).
Most critical respiratory comorbidities according to the CDC, are: moderate or severe asthma, pre-existing COPD, pulmonary fibrosis, cystic fibrosis. Evidence stemming from meta-analysis of several smaller research papers also suggests that smoking can be associated with worse outcomes. When someone with existing respiratory problems is infected with COVID-19, they might be at greater risk for severe symptoms. COVID-19 also poses a greater risk to people who misuse opioids and methamphetamines, insofar as their drug use may have caused lung damage.
In August 2020 the CDC issued a caution that tuberculosis infections could increase the risk of severe illness or death. The WHO recommended that people with respiratory symptoms be screened for both diseases, as testing positive for COVID-19 couldn't rule out co-infections. Some projections have estimated that reduced TB detection due to the pandemic could result in 6.3 million additional TB cases and 1.4 million TB related deaths by 2025.
The virus is thought to be natural and of an animal origin,
through spillover infection. There are several theories about where the first case (the so-called patient zero) originated. Phylogenetics estimates that SARS-CoV-2 arose in October or November 2019. Evidence suggests that it descends from a coronavirus that infects wild bats, and spread to humans through an intermediary wildlife host.
The first known human infections were in Wuhan, Hubei, China. A study of the first 41 cases of confirmed COVID-19, published in January 2020 in ''The Lancet'', reported the earliest date of onset of symptoms as 1December 2019. Official publications from the WHO reported the earliest onset of symptoms as 8December 2019. Human-to-human transmission was confirmed by the WHO and Chinese authorities by 20 January 2020. According to official Chinese sources, these were mostly linked to the Huanan Seafood Wholesale Market, which also sold live animals. In May 2020 George Gao, the director of the CDC, said animal samples collected from the seafood market had tested negative for the virus, indicating that the market was the site of an early superspreading event, but that it was not the site of the initial outbreak. Traces of the virus have been found in wastewater samples that were collected in Milan and Turin, Italy, on 18 December 2019.
By December 2019, the spread of infection was almost entirely driven by human-to-human transmission. The number of coronavirus cases in Hubei gradually increased, reaching 60 by 20 December, and at least 266 by 31 December. On 24 December, Wuhan Central Hospital sent a bronchoalveolar lavage fluid (BAL) sample from an unresolved clinical case to sequencing company Vision Medicals. On 27 and 28 December, Vision Medicals informed the Wuhan Central Hospital and the Chinese CDC of the results of the test, showing a new coronavirus. A pneumonia cluster of unknown cause was observed on 26 December and treated by the doctor Zhang Jixian in Hubei Provincial Hospital, who informed the Wuhan Jianghan CDC on 27 December. On 30 December, a test report addressed to Wuhan Central Hospital, from company CapitalBio Medlab, stated an erroneous positive result for SARS, causing a group of doctors at Wuhan Central Hospital to alert their colleagues and relevant hospital authorities of the result. The Wuhan Municipal Health Commission issued a notice to various medical institutions on "the treatment of pneumonia of unknown cause" that same evening. Eight of these doctors, including Li Wenliang (punished on 3January), were later admonished by the police for spreading false rumours and another, Ai Fen, was reprimanded by her superiors for raising the alarm.
The Wuhan Municipal Health Commission made the first public announcement of a pneumonia outbreak of unknown cause on 31 December, confirming 27 cases —enough to trigger an investigation.
During the early stages of the outbreak, the number of cases doubled approximately every seven and a half days. In early and mid-January 2020, the virus spread to other Chinese provinces, helped by the Chinese New Year migration and Wuhan being a transport hub and major rail interchange. On 20 January, China reported nearly 140 new cases in one day, including two people in Beijing and one in Shenzhen. Later official data shows 6,174 people had already developed symptoms by then, and more may have been infected. A report in ''The Lancet'' on 24 January indicated human transmission, strongly recommended personal protective equipment for health workers, and said testing for the virus was essential due to its "pandemic potential". On 30 January, the WHO declared the coronavirus a Public Health Emergency of International Concern. By this time, the outbreak spread by a factor of 100 to 200 times.
Italy had its first confirmed cases on 31 January 2020, two tourists from China. As of 13 March 2020 the WHO considered Europe the active centre of the pandemic. Italy overtook China as the country with the most deaths on 19 March 2020 . By 26 March the United States had overtaken China and Italy with the highest number of confirmed cases in the world. Research on coronavirus genomes indicates the majority of COVID-19 cases in New York came from European travellers, rather than directly from China or any other Asian country. Retesting of prior samples found a person in France who had the virus on 27 December 2019, and a person in the United States who died from the disease on 6February 2020.
RT-PCR testing of untreated wastewater samples from Brazil and Italy have suggested detection of SARS-CoV-2 as early as November and December 2019, respectively, but the methods of such sewage studies have not been optimised, many have not been peer reviewed, details are often missing, and there is a risk of false positives due to contamination or if only one gene target is detected. A September 2020 review journal article said, "The possibility that the COVID-19 infection had already spread to Europe at the end of last year is now indicated by abundant, even if partially circumstantial, evidence", including pneumonia case numbers and radiology in France and Italy in November and December.
After the initial outbreak of COVID-19, misinformation and disinformation regarding the origin, scale, prevention, treatment, and other aspects of the disease rapidly spread online.
In September 2020, the U.S. CDC published preliminary estimates of the risk of death by age groups in the United States, but those estimates were widely misreported and misunderstood.
Humans appear to be capable of spreading the virus to some other animals, a type of disease transmission referred to as zooanthroponosis.
Some pets, especially cats and ferrets, can catch this virus from infected humans.
Symptoms in cats include respiratory (such as a cough) and digestive symptoms. Cats can spread the virus to other cats, and may be able to spread the virus to humans, but cat-to-human transmission of SARS-CoV-2 has not been proven. Compared to cats, dogs are less susceptible to this infection. Behaviors which increase the risk of transmission include kissing, licking, and petting the animal.
The virus does not appear to be able to infect pigs, ducks, or chickens at all. Mice, rats, and rabbits, if they can be infected at all, are unlikely to be involved in spreading the virus.
Tigers and lions in zoos have become infected as a result of contact with infected humans. As expected, monkeys and great ape species such as orangutans can also be infected with the COVID-19 virus.
Minks, which are in the same family as ferrets, have been infected. Minks may be asymptomatic, and can also spread the virus to humans. Multiple countries have identified infected animals in mink farms. Denmark, a major producer of mink pelts, ordered the slaughter of all minks over fears of viral mutations. A vaccine for mink and other animals is being researched.
International research on vaccines and medicines in COVID-19 is underway by government organisations, academic groups, and industry researchers.
The CDC has classified it to require a BSL3 grade laboratory. There has been a great deal of COVID-19 research, involving accelerated research processes and publishing shortcuts to meet the global demand.
, hundreds of clinical trials have been undertaken, with research happening on every continent except Antarctica. , more than 200 possible treatments had been studied in humans so far.
Transmission and prevention research
Modelling research has been conducted with several objectives, including predictions of the dynamics of transmission, diagnosis and prognosis of infection, estimation of the impact of interventions, or allocation of resources. Modelling studies are mostly based on epidemiological models, estimating the number of infected people over time under given conditions. Several other types of models have been developed and used during the COVID-19 including computational fluid dynamics models to study the flow physics of COVID-19, retrofits of crowd movement models to study occupant exposure, mobility-data based models to investigate transmission, or the use of macroeconomic models to assess the economic impact of the pandemic. Further, conceptual frameworks from crisis management research have been applied to better understand the effects of COVID-19 on organizations worldwide.
Repurposed antiviral drugs make up most of the research into COVID-19 treatments.
Other candidates in trials include vasodilators, corticosteroids, immune therapies, lipoic acid, bevacizumab, and recombinant angiotensin-converting enzyme 2.
In March 2020, the World Health Organization (WHO) initiated the Solidarity trial to assess the treatment effects of some promising drugs: an experimental drug called remdesivir; anti-malarial drugs chloroquine and hydroxychloroquine; two anti-HIV drugs, lopinavir/ritonavir; and interferon-beta. More than 300 active clinical trials are underway as of April 2020.
Research on the antimalarial drugs hydroxychloroquine and chloroquine showed that they were ineffective at best, and that they may reduce the antiviral activity of remdesivir. , France, Italy, and Belgium had banned the use of hydroxychloroquine as a COVID-19 treatment.
In June, initial results from the randomised RECOVERY Trial in the United Kingdom showed that dexamethasone reduced mortality by one third for people who are critically ill on ventilators and one fifth for those receiving supplemental oxygen. Because this is a well-tested and widely available treatment, it was welcomed by the WHO, which is in the process of updating treatment guidelines to include dexamethasone and other steroids. Based on those preliminary results, dexamethasone treatment has been recommended by the NIH for patients with COVID-19 who are mechanically ventilated or who require supplemental oxygen but not in patients with COVID-19 who do not require supplemental oxygen.
In September 2020, the WHO released updated guidance on using corticosteroids for COVID-19. The WHO recommends systemic corticosteroids rather than no systemic corticosteroids for the treatment of people with severe and critical COVID-19 (strong recommendation, based on moderate certainty evidence). The WHO suggests not to use corticosteroids in the treatment of people with non-severe COVID-19 (conditional recommendation, based on low certainty evidence). The updated guidance was based on a meta-analysis of clinical trials of critically ill COVID-19 patients.
In September 2020, the European Medicines Agency (EMA) endorsed the use of dexamethasone in adults and adolescents from twelve years of age and weighing at least who require supplemental oxygen therapy. [ Text was copied from this source which is European Medicines Agency. Reproduction is authorized provided the source is acknowledged.] Dexamethasone can be taken by mouth or given as an injection or infusion (drip) into a vein.
In November 2020, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization for the investigational monoclonal antibody therapy bamlanivimab for the treatment of mild-to-moderate COVID-19. [ ] Bamlanivimab is authorized for people with positive results of direct SARS-CoV-2 viral testing who are twelve years of age and older weighing at least , and who are at high risk for progressing to severe COVID-19 or hospitalization. This includes those who are 65 years of age or older, or who have chronic medical conditions.
A cytokine storm can be a complication in the later stages of severe COVID-19. A cytokine storm is a potentially deadly immune reaction where a large amount of pro-inflammatory cytokines and chemokines are released too quickly; A cytokine storm can lead to ARDS and multiple organ failure. Data collected from Jin Yin-tan Hospital in Wuhan, China indicates that patients who had more severe responses to COVID-19 had greater amounts of pro-inflammatory cytokines and chemokines in their system than patients who had milder responses; These high levels of pro-inflammatory cytokines and chemokines indicate presence of a cytokine storm.
Tocilizumab has been included in treatment guidelines by China's National Health Commission after a small study was completed.
It is undergoing a PhaseII non-randomised trial at the national level in Italy after showing positive results in people with severe disease. Combined with a serum ferritin blood test to identify a cytokine storm (also called cytokine storm syndrome, not to be confused with cytokine release syndrome), it is meant to counter such developments, which are thought to be the cause of death in some affected people. [Various sources:
* ] The interleukin-6 receptor antagonist was approved by the FDA to undergo a PhaseIII clinical trial assessing its effectiveness on COVID-19 based on retrospective case studies for the treatment of steroid-refractory cytokine release syndrome induced by a different cause, CAR T cell therapy, in 2017. To date, there is no randomised, controlled evidence that tocilizumab is an efficacious treatment for CRS. Prophylactic tocilizumab has been shown to increase serum IL-6 levels by saturating the IL-6R, driving IL-6 across the blood-brain barrier, and exacerbating neurotoxicity while having no effect on the incidence of CRS.
Lenzilumab, an anti-GM-CSF monoclonal antibody, is protective in murine models for CAR T cell-induced CRS and neurotoxicity and is a viable therapeutic option due to the observed increase of pathogenic GM-CSF secreting T-cells in hospitalised patients with COVID-19.
Transferring purified and concentrated antibodies produced by the immune systems of those who have recovered from COVID-19 to people who need them is being investigated as a non-vaccine method of passive immunisation.
Viral neutralization is the anticipated mechanism of action by which passive antibody therapy can mediate defence against SARS-CoV-2. The spike protein of SARS-CoV-2 is the primary target for neutralizing antibodies. As of 8 August 2020, eight neutralizing antibodies targeting the spike protein of SARS-CoV-2 have entered clinical studies. It has been proposed that selection of broad-neutralizing antibodies against SARS-CoV-2 and SARS-CoV might be useful for treating not only COVID-19 but also future SARS-related CoV infections. Other mechanisms, however, such as antibody-dependent cellular cytotoxicity and/or phagocytosis, may be possible. Other forms of passive antibody therapy, for example, using manufactured monoclonal antibodies, are in development.
The use of passive antibodies to treat people with active COVID-19 is also being studied. This involves the production of convalescent serum, which consists of the liquid portion of the blood from people who recovered from the infection and contains antibodies specific to this virus, which is then administered to current patients. This strategy was tried for SARS with inconclusive results. A Cochrane review in October 2020, found insufficient evidence to recommend for or against this treatment in COVID-19, due in large part to the methodology of the clinical trials conducted so far. Specifically, there are no trials yet conducted for which the safety of convalescent serum administration to people with COVID-19 can be determined, and the differing outcomes measured in different studies limits their use in determining efficacy.
Effect on other diseases and the pharmacy trade
There was a report
on 3 March 2021, that social distancing and common wearing of surgical masks and similar as a common precaution against COVID-19 caused such a drop in the spread rate of the common cold and flu that in Britain the sale of cough liquids and throat lozenges and decongestants from 30 November 2020 to 21 February 2021, was about a half of the sale a year earlier, and that Public Health England reported no cases of flu in year 2021 to date, and that there was an 89% rise in sales of Vitamin D to try to boost immunity.
* Coronavirus diseases, a group of closely related syndromes
* Disease X, a WHO term
Coronavirus disease (COVID-19)FACTS
by the World Health Organization (WHO)
Coronavirus 2019 (COVID-19)
by the US Centers for Disease Control and Prevention (CDC)
by the UK National Health Service (NHS)
Coronavirus Resource Center
at the Center for Inquiry
COVID-19 Resource Directory on OpenMD
Coronavirus Disease 2019 (COVID-19)
BMJ's Coronavirus (covid-19) Hub
by the BMJ
Novel Coronavirus Information Center
COVID-19 Resource Centre
by ''The Lancet''
Coronavirus (COVID-19) Research Highlights
by Springer Nature
by ''The New England Journal of Medicine''
Covid-19: Novel Coronavirus
by Wiley Publishing
Category:Occupational safety and health
Category:Viral respiratory tract infections